(NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has ...

Labeling is based on the agency's thorough analysis of the new drug application (NDA) or biological license application. The labeling, or prescribing information, is thus subject to FDA ...

Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market ...

Studying synapses in live human brains is crucial for understanding many psychiatric disorders. Now, using positron emission ...

John Wilkins, clinical director at the institute’s Human Longevity Laboratory, puts it like this: “When you ask how old ...

People are spending thousands of dollars on unproven exosome therapies for hair loss, skin aging, and acne, as well as more serious conditions like long covid and Alzheimer’s.

Additional interested parties are encouraged to schedule a meeting through the conference partnering platform or to email Scinai at [email protected] to schedule a meeting. Throughout the conference, ...

Project Title Fragment and structure-based hit generation platform for new malaria targets Collaboration Partners 1.

As a specialty Contract Development and Manufacturing Organization, Tanvex CDMO excels in the development, scale-up, and transition from clinical to commercial GMP manufacturing. With a proven track ...

With another Biological License Application (BLA) pending U.S. FDA approval, Tanvex's journey is characterized by an unwavering commitment to excellence, innovation, and a passion for improving ...

To do the full dotting the I and crossing the T's of a biological license application, the BLA, that would take several more months to do. So when you do an EUA, particularly an EUA that's granted ...